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We thank Drs. Krejci and Mayer for highlighting
the potential value of considering serum aminotrans-
ferase enzyme (AST, ALT) concentrations in assessing
outcomes of treatment for acute graft-versus-host
disease (GVHD) of the liver. Liver GVHD has 3 com-
ponents [1]. The first involves a cytokine-mediated
effect on hepatocyte transport of conjugated bilirubins
into bile, primarily in patients with more severe gut
GVHD. These cases present as isolated hyperbilirubi-
nemia (cholestasis) with no histologic findings [2]. The
second involves T cell-mediated apoptosis of small bile
duct epithelial cells [2], with hyperbilirubinemia as
the principal clinical biomarker. The third involves
T cell-mediated hepatocyte necrosis and lobular
inflammation, also described as hepatitic GVHD,
often occurring together with bile duct injury and
hyperbilirubinemia.
Serum AST and ALT elevations may presage the
development of acute GVHD before day 100, and can
dominate the clinical presentation of liver GVHD dur-
ing withdrawal of cyclosporine or tacrolimus or after
donor lymphocyte infusion. Extreme AST or ALT
elevation without hyperbilirubinemia before day 100 is
rarely, if ever, caused by GVHD [3]. Serum AST and
ALT elevation lacks specificity as a marker of liver
GVHD, because these abnormalities can have many
other causes in transplant recipients, including drug
injury, cholangitis lenta, biliary sludge disease, vascular
liver injury, infection by herpesviruses and adenovirus,
and flares of hepatitis C or B after immune reconstitu-
tion [1]. We acknowledge that similar problems occurwith the use of hyperbilirubinemia as a marker of liver
GVHD, although we believe that this abnormality has
better specificity than AST or ALT elevation, particu-
larly in patients who receive ursodiol to prevent hepatic
complications after transplantation [4,5]. Because
GVHD seldom occurs in complete isolation, tests lack-
ing specificity are not well suited to measure treatment
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